Mifepristone Reduces Insulin Resistance in Patient Volunteers with Adrenal Incidentalomas That Secrete Low Levels of Cortisol: A Pilot Study

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Debono, Miguel ^a   Chadarevian, Rita ^c   Eastell, Richard ^b   Ross, Richard J ^a   Newell Price, John ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c Laboratoire HRA Pharma   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MIFEPRISTONE; THYROTROPIN;

ADRENAL INCIDENTALOMA; ADULT; AGED; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMAN; HYDROCORTISONE RELEASE; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LASSITUDE; MALE; MORNING DOSAGE; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PILOT STUDY; PROSPECTIVE STUDY; SHORT COURSE THERAPY; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION;

ADRENAL GLAND NEOPLASMS; AGED; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMUS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MIFEPRISTONE; PILOT PROJECTS; PITUITARY-ADRENAL SYSTEM; SAFETY; TUMOR MARKERS, BIOLOGICAL;

EID: 84875931797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060984     Document Type: Article

References (39)

1. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, et al. (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25: 309-340.
2. Young WF Jr, (2007) Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356: 601-610.
3. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, et al. (2011) AME position statement on adrenal incidentaloma. Eur J Endocrinol 164: 851-870.
4. Newell-Price J, Bertagna X, Grossman AB, Nieman LK, (2006) Cushing's syndrome. Lancet 367: 1605-1617.
5. Friedman JE, Yun JS, Patel YM, McGrane MM, Hanson RW, (1993) Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J Biol Chem 268: 12952-12957.
6. Vander Kooi BT, Onuma H, Oeser JK, Svitek CA, Allen SR, et al. (2005) The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol 19: 3001-3022.
7. Davani B, Khan A, Hult M, Martensson E, Okret S, et al. (2000) Type 1 11beta-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem 275: 34841-34844.
8. Qi D, Rodrigues B, (2007) Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 292: E654-667.
9. Nosadini R, Del Prato S, Tiengo A, Valerio A, Muggeo M, et al. (1983) Insulin resistance in Cushing's syndrome. J Clin Endocrinol Metab 57: 529-536.
10. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K, (2000) Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 20: 538-544.
11. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, et al. (2002) Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab 87: 4872-4878.
12. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, et al. (2012) Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome. J Clin Endocrinol Metab.
13. Chiodini I, (2011) Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 96: 1223-1236.
14. Des Jarlais DC, Lyles C, Crepaz N, (2004) Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 94: 361-366.
15. Kawai S, Nieman LK, Brandon DD, Udelsman R, Loriaux DL, et al. (1987) Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J Pharmacol Exp Ther 241: 401-406.
16. Heikinheimo O, (1997) Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet 33: 7-17.
17. Newell-Price J, Trainer P, Besser M, Grossman A, (1998) The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19: 647-672.
18. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526-1540.
19. Gordon BA, Fraser SF, Bird SR, Benson AC, (2011) Reproducibility of multiple repeated oral glucose tolerance tests. Diabetes Res Clin Pract 94: e78-82.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
21. Matsuda M, DeFronzo RA, (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470.
22. Perogamvros I, Owen LJ, Newell-Price J, Ray DW, Trainer PJ, et al. (2009) Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: application in basal and stimulated conditions. J Chromatogr B Analyt Technol Biomed Life Sci 877: 3771-3775.
23. Muniyappa R, Lee S, Chen H, Quon MJ, (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294: E15-26.
24. Tsagarakis S, Roboti C, Kokkoris P, Vasiliou V, Alevizaki C, et al. (1998) Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Clin Endocrinol (Oxf) 49: 165-171.
25. Di Dalmazi G, Vicennati V, Rinaldi E, Morselli-Labate AM, Giampalma E, et al. (2012) Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol 166: 669-677.
26. Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, et al. (2010) Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95: 2736-2745.
27. Stewart PM, (2010) Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J Clin Endocrinol Metab 95: 2618-2620.
28. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T, (2001) The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 54: 797-804.
29. Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, et al. (2000) Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 85: 1440-1448.
30. Terzolo M, Pia A, Ali A, Osella G, Reimondo G, et al. (2002) Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab 87: 998-1003.
31. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F, et al. (2009) Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann Surg 249: 388-391.
32. Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Savoca C, et al. (2010) Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf) 73: 161-166.
33. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, et al. (2008) Accuracy of diagnostic tests for Cushing's syndrome: a systematic review and metaanalyses. J Clin Endocrinol Metab 93: 1553-1562.
34. Reimondo G, Allasino B, Bovio S, Saba L, Ardito A, et al. (2011) Pros and cons of dexamethasone suppression test for screening of subclinical Cushing's syndrome in patients with adrenal incidentalomas. J Endocrinol Invest 34: e1-5.
35. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH, (1993) Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 153: 578-581.
36. Lawes CM, Bennett DA, Feigin VL, Rodgers A, (2004) Blood pressure and stroke: an overview of published reviews. Stroke 35: 1024.
37. Whitworth JA, Brown MA, Kelly JJ, Williamson PM, (1995) Mechanisms of cortisol-induced hypertension in humans. Steroids 60: 76-80.
38. Kumai T, Asoh K, Tateishi T, Tanaka M, Watanabe M, et al. (2000) Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats. Life Sci 67: 1993-1999.
39. Page ST, Krauss RM, Gross C, Ishida B, Heinecke JW, et al. (2012) Impact of mifepristone, a glucocorticoid/progesterone antagonist, on HDL cholesterol, HDL particle concentration, and HDL function. J Clin Endocrinol Metab 97: 1598-1605.